34 citations
,
May 1987 in “European Journal of Pediatrics” This study concluded that Buserelin can effectively inhibit gonadal activity in children with central precocious puberty over 18 months, potentially improving final height predictions with prolonged treatment.
3 citations
,
October 2024 in “Advances in Therapy” In this study, Chinese children with central precocious puberty receiving 6-monthly injections of triptorelin showed luteinizing hormone suppression and slowed development of sexual characteristics over 12 months, without severe adverse events, suggesting it may be an effective treatment option for this population.
July 2026 in “Clinical Cosmetic and Investigational Dermatology” In this case report, a 9-year-old boy with Sjogren-Larsson syndrome was also diagnosed with central precocious puberty, showing genetic mutations and increased hormone levels; he was treated with triptorelin acetate for CPP but experienced growth delay during follow-up.
January 2026 in “International Journal of Women s Health” This study found that a nomogram prediction model based on clinical characteristics, bone metabolism, and ovarian function can effectively predict the treatment response to long-acting GnRHa in girls with idiopathic central precocious puberty.
October 2023 in “BMC endocrine disorders” In this case study, researchers observed a 5.8-year-old male with peripheral precocious puberty due to a germ cell tumor, marked by elevated human chorionic gonadotropin levels. Treatment normalized hormone levels and arrested the puberty progression, highlighting melatonin's potential role in transitions to central precocious puberty.